BioCentury
ARTICLE | Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

August 26, 2016 7:00 AM UTC

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks compared with placebo in the study, which enrolled 252 patients with chronic diabetic foot ulcers.

Adocia is halting all of its programs in diabetic foot ulcers, which it called "extremely difficult" to treat. ...